News
On January 29–30, 2026, we had the privilege of bringing together patients, advocates, clinicians, and industry partners in Phoenix, Arizona, for the Updates in…
AbstractThe escalating global trend of aging populations has brought attention to the rising prevalence of late-onset amyloid disorders. Among them, amyloid…
BridgeBio Pharma has secured a $300 million upfront payment through a royalty financing agreement with HealthCare Royalty and Blue Owl Capital, which will bolster…
AbstractAlzheimer’s disease (AD) is the most prevalent neurodegenerative disorder. Antiamyloid antibody treatments modestly slow disease progression in mild…
Cardiac Amyloidosis - What You Need to Know
January 20, 2024
12PM - 2:30PM ET
Please join Amyloidosis Support Groups on January 20th from 12:00 pm - 2:30 pm ET for…
Calquence six-year follow-up data reinforce long-term benefit in chronic lymphocytic
leukaemia, and data across multiple haematology assets showcase breadth of…
We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.
This symposium is organized as a hybrid meeting (with the focus…
Nashville Support Group Meeting
Saturday, December 2nd, 2023
12:00 - 2:00 pm CT
Presenters:
Jon Wall and Emily Martin UT Knoxville: Ongoing Clinical Trials:…
Hereditary transthyretin (hATTR) amyloidosis, also known as variant ATTR (ATTRv) amyloidosis, is a rare disease affecting about 50,000 people worldwide. It's caused…
